4.7 Article

Network-based prioritization of cancer biomarkers by phenotype-driven module detection and ranking

期刊

出版社

ELSEVIER
DOI: 10.1016/j.csbj.2021.12.005

关键词

Phenotype-driven module detection; Block-based module ranking; Network biotechnology; Machine learning; Biomarker discovery

资金

  1. National Key Research and Development Program of China [2020YFA0712402]
  2. National Natural Science Foundation of China [61973190, 61572287]
  3. Shandong Provincial Key Research and Development Program (Major Scientific and Technological Innovation Project) [2019JZZY010423]
  4. Natural Science Foundation of Shandong Province of China [ZR2020ZD25]
  5. Innovation Method Fund of China (Ministry of Science and Technology of China) [2018IM020200]
  6. Program of Qilu Young Scholar of Shandong University

向作者/读者索取更多资源

This paper presents an ensemble method for reliable network-based biomarker discovery, using supervised module detection and module prioritization. The authors successfully identify hepatocellular carcinoma (HCC) network modules as diagnostic biomarkers and validate their effectiveness on gene regulatory networks. The results demonstrate the ability of the method to find effective network biomarkers for cancer diagnosis with fewer false positives.
This paper describes an ensemble method with supervised module detection and further module prioritization for reliable network-based biomarker discovery. We design a module detection and ranking method called mRank to discover reliable network modules as cancer diagnostic biomarkers, with two procedures: (1) an iterative supervised module detection guided by phenotypic states in a specific network, (2) a block-based module ranking locally and globally via network topological centrality. We validate its effectiveness and efficiency by identifying hepatocellular carcinoma (HCC) network modules on a comprehensive gene regulatory network with specifying gene interactions by HCC RNA-seq data from the Cancer Genome Atlas (TCGA). These top-ranked modules by mRank get a mean AUC of 0.995 on TCGA HCC dataset with 371 tumor samples and 50 controls by cross-validation SVM. Based on the prior knowledge of cancer dysfunctions enriched in top-ranked modules, 69 genes are identified as HCC candidate biomarkers. They are further validated in independent cohorts with a classifier trained on TCGA HCC dataset. A mean AUC of 0.846 is achieved in distinguishing 976 disease samples from 827 controls. Moreover, some known HCC signatures such as AFP and SPP1 are also included in our identified biomarkers. mRank enables us to find more reliable network modules for cancer diagnosis. For a proof-of-concept study, we validate it in identifying HCC network biomarkers and it is generalizable to other cancers or complex disease. The overall results have demonstrated that mRank can find effective network biomarkers for cancer diagnosis which result in less false positives.(c) 2021 The Author(s). Published by Elsevier B.V. on behalf of Research Network of Computational and Structural Biotechnology. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据